Biological Material Analysis TRIZ Cases

Encapsulating the dye inside the protein cavity prevents aggregation and displacement by hemin, maintaining high fluorescence intensity in water.

A method converts single-stranded polynucleotides to double-stranded fragments using polymerase extension and complementary overhangs for precise joining.

Ionizing angiotensin I via mass spectrometry eliminates nonspecific binding errors from antibody assays, ensuring accurate renin measurement.

Polyclonal antibodies detect capsular polysaccharides of Neisseria meningitidis serogroup X in biological fluids without culture.

A conjugate pad features a line-shaped section in contact with the membrane support to release reagents efficiently.

EC-ELISA uses anti-fibrinogen capture and anti-alpha2-antiplasmin detection to measure factor XIII activity with high sensitivity.

A competing drug blocking antibody neutralizes interfering molecules before detection, ensuring accurate neutralizing antibody quantitation.

A divalent antibody with a modified hinge region binds the c-Met receptor to block its dimerization.

Stable isotope-labeled proinsulin intermediates serve as internal standards to eliminate cross-reactivity errors during mass spectrometric quantification.

Multiplex aptamer assays detect specific protein concentrations to resolve pre-analytical variability in biomarker research.

Antibodies block the PD-1 pathway to restore T-cell effector function despite sustained inhibitory receptor expression.

A 4F6 monoclonal antibody recognizes specific Trop-2 epitopes to inhibit cancer cell growth directly.

A liposome-based particle collection detects pathogen-neutralizing antibodies through specific molecular recognition mechanisms.

Administering cytokines mobilizes tumor cells and DNA into circulation, resolving low sensitivity in minimal residual disease detection.

Targeted antibodies inhibit tumor metastasis by blocking ENO1-plasminogen interaction, reducing cell invasion by 70%.

Surface peptide coating on adenoviral vectors redirects the immune response from viral components to tumor antigens, overcoming immune dominance limitations.

Monoclonal antibody targeting Trop2 binds tumor cells with high affinity using hybridoma technology.

Murine monoclonal antibody 11B9 targets major neutralizing epitopes on influenza A H7 hemagglutinin to prevent viral infection.

A specific polypeptide binds phosphatidylserine on apoptotic and tumor cells to enable targeted detection and drug delivery applications.

A wristwatch integrates a blood sugar meter and strip connector to automate glucose measurement.

A latex agglutination particle features a hydrated copolymer surface layer that forms a swollen barrier to reduce nonspecific adsorption.

A programmable bio-nano-chip system quantifies cellular morphometric data and molecular biomarkers from brush biopsy samples using integrated microfluidics.

Humanized antibodies bind specific CD4 receptor regions to selectively activate regulatory T cells.

Monoclonal antibodies bind tissue plasminogen activator to selectively inhibit fibrin-dependent plasminogen activation.

Pretreating tumor biopsies with stress conditions increases immunogenicity, resolving unpredictable treatment outcomes caused by immune evasion variability.

Anti-human MUC1 antibody Fab fragment with specific variable regions maintains high binding affinity for cancer diagnosis.

Sandwich ELISA assay using monoclonal antibodies targeting laminaritetraose epitopes on beta-D-glucan molecules.

The N297A mutation creates an aglycosylated 3G4NA antibody that blocks CD16 receptors without triggering cell activation or adverse reactions.

A cytokine fingerprint using IP-10, PDGF-BB, and IL-4 markers enables rapid identification of SARS-CoV-2 infection in plasma samples.

Photoreactive and cleavable probes use light-activated warheads to tag biomolecules, reducing nonspecific binding and preserving natural cell environments.

Dual-ligand heterobiligands merge peptide and folate moieties to increase binding specificity, reducing off-target effects in cancer therapy.

Fluorophore-conjugated beta-lactones label specific PBPs in vivo, resolving the trade-off between activity state information and visualization.

Self-hydrating sensor cartridge detects airborne viruses through electron hopping, eliminating PCR reagent waste and latency.

Bifunctional crosslinkers anchor proteins to swellable gels, preserving fluorescent signals during proteolytic digestion.

Replacing invasive imaging with MMP-7 biomarker detection resolves diagnostic reliability and cost trade-offs.

Camelid-derived single chain antibody domains bind botulinum neurotoxins to form detectable complexes, enabling detection below 1 pg/mL.

Replacing complex HPLC systems, the aptamer enables low-cost detection with high specificity and affinity.

Moving a single tip cover extends a housing opening and automatically unlocks a cassette door, eliminating complex multi-step locking mechanisms.

Disposable immunosensing cartridge integrates sample dilution and multiple analyte detection zones for rapid point-of-care diagnostics.

A leaky mode waveguide sensor uses molecular imprinting to detect target entities via refractive index changes.

A two-step filtration method concentrates target bacteria from food matrices using protease degradation to simplify the sample matrix.

Erythrocyte quantitative evaluation unit measures hematocrit value using electrical characteristics at 2 to 25 MHz.

A coplanar probe sensor measures dielectric properties of biological materials using microwave frequencies.

Phosphorylated syndecan-4 cytoplasmic domain generates nuclear localization signals to deliver bound agents into the nucleus.

A paper-based assay device uses an enzyme activator to trigger a zymogen amplifier for signal generation.

Consensus amino acid substitutions enable synthetic odorant receptors to bypass endoplasmic reticulum retention and achieve robust cell surface expression.

Maskless light-directed synthesis creates peptide arrays to identify specific binders, reducing discovery time and contamination risks.

IHC biomarker assay stratifies breast cancer patients into risk categories using specific protein expression levels.

Synthesized aptamers replace antibodies in disposable test devices to resolve the contradiction between detection reliability and point-of-care stability.

Fluorescein labeled anti-HK2 antibodies stain rare tumor cells, overcoming epithelial marker limitations to detect interstitial origin tumors.